POCT INR glucose EQALM 2005 sendt

Information about POCT INR glucose EQALM 2005 sendt

Published on October 29, 2007

Author: Nastasia

Source: authorstream.com

Content

Slide1:  POCT EQA for coagulation and glucose on the level of physicians and patients - is it possible? Sverre Sandberg Norwegian Quality Improvement of Primary Care Laboratories (NOKLUS) and Lab. Clin. Biochem. Haukeland University Hospital and NOKLUS, Bergen, Norway EQALM Rome, 2005 Similar “problems” with POC EQAS for PT-INR and Glucose:  Similar “problems” with POC EQAS for PT-INR and Glucose Control material A lot of different instruments using whole blood Lot to lot variation SO Why are we doing EQAS? Are we doing more good than harm? Should we extend to P-EQAS? EQAS for office laboratories and hospital laboratories - what is the difference:  EQAS for office laboratories and hospital laboratories - what is the difference EQAS for Primary health care General Practitioners Office personell, Nurses NOKLUS - some numbers - 2004:  NOKLUS - some numbers - 2004 2200 participants from PHC (99.7%), 86 hospital labs About 5000 physicians 1288 visits in PHC by lab.consultants 140 courses with 3627 participants And what about you?:  And what about you? Do physicians in your home country analyse prothrombin time in their offices? Do you have an EQA system for this Do patients in your home country analyse prothrombin time? Do you have an EQA system for this? Prothrombin time (PT-INR):  Prothrombin time (PT-INR) How can POC EQAS be carried out for PT-INR? Control material Split sample or traditional EQA? Physicians offices and patients Quality specifications Post-analytical EQA Van der Besselaar. J.Thromb. Thrombolysis. 2001;12:35-40:  Van der Besselaar. J.Thromb. Thrombolysis. 2001;12:35-40 Quality control (QC) materials for POC devices are different from patients’ samples and may not exactly reflect the real clinical situation. Nevertheless, internal and external QC schemes for POC devices are valuable to investigate their performance in daily practice. Calibration can be improved by direct comparison of a POC system against an established international reference preparation method. Number of participants with different instruments:  Number of participants with different instruments Control material are we assessing the right things right?:  Control material are we assessing the right things right? Different types of instrument use different control materials patient like material is difficult fresh / frozen plasma not possible. lyophilized, dissolved material? Slide10:  Thrombotest: Lot to lot variation (99% CI) Split sample compared to traditional EQA:  Split sample compared to traditional EQA Traditional EQA is influenced by Control material /dilution / dissolution Analytical procedure Advantage: Few variables, same level and easy to compare Disadvantage: Control material, and the whole procedure is not taken into account Split sample compared to traditional EQA:  Split sample compared to traditional EQA Split sample is influenced by Sampling procedure* Analytical procedure Sending procedure* Conventional reference method procedure* Advantage: Native material, whole procedure taken into account Disadvantage: Many variables, different levels, less easy to organise. TO BE ABLE TO COMPARE:  TO BE ABLE TO COMPARE QUALITY SPECIFICATIONS HAVE TO EXPANDED FROM THE CONVENTIONAL EQA METHOD TAKING THE VARIANCE IN BLOOD SAMPLING, SENDING AND CONVENTIONAL REFERENCE METHOD INTO ACCOUNT Patient self -testing Coagucheck:  Patient self -testing Coagucheck Tripodi et al.Thrombosis Research 2004; 111: 35-40 Patient self-testing: Difference between ProTime and laboratory INR vs laboratory INR. :  Patient self-testing: Difference between ProTime and laboratory INR vs laboratory INR. Sunderji et al. Am. J. Clin Pathol 2005;124: 184-8 WHAT shall we look for? :  WHAT shall we look for? Only analytical quality? OR ALSO How tests are interpreted? Cartoon by courtesy of Amanda Burls Slide17:  Clinical Findings Interpretation Test requesting Pre-analytical phase Analysing Test report Diagnosing Monitoring Slide18:  External quality assessment programmes should, as far as possible provide clinically relevant challenges that mimic patient samples and have the effect of checking the entire examination process, including pre- ad post-examination procedures Glucose:  Glucose And what about you?:  And what about you? Do physicians in your home country analyse glucose in their offices? Do you have an EQA system for this? Do patients in your home country analyse glucose? Do you have an EQA system for this? Problems - glucose Evaluation of participant or evaluation of instrument?:  Problems - glucose Evaluation of participant or evaluation of instrument? Native material is not possible / difficult Target values from reference methods can not be used - i.e. method-specific target values are usually used Lot to lot variation What is a method specific target value? :  Kristensen et al Clin Chem 2005; 51: 1632-6 What is a method specific target value? What is a method specific target?:  What is a method specific target? The median after exclusion of outlier results? The median after exclusion of some of the lots? The median after exclusion of outliers for each lot? What are we evaluating?:  What are we evaluating? The participants? - then ideally there should be a lot specific target. With a method specific target, we are evaluating both lot to lot variation as well as participant performance Consequences::  Consequences: Do differences found between lots using the control material also reflect differences between lots when native material is used? :  Do differences found between lots using the control material also reflect differences between lots when native material is used? Do the lot to lot differences reflect results when capillary blood is used? :  Kristensen et al Clin Chem 2005; 51: 1632-6 Do the lot to lot differences reflect results when capillary blood is used? Slide30:  Kristensen et al Clin Chem 2005; 51: 1632-6 Slide31:  Case stories distributed in: Hungary Norway Sweden The Netherlands Australia Spain South-Africa Slide32:  A 64-year-old man, somewhat overweight. He tells you that his mother had diabetes when she was “well on in years”. He himself feels fit, but he would like to have his blood sugar measured. Thus, he has had the foresight to come fasting to this morning consultation. He has never been seriously ill previously and he takes no regular medication. Blood pressure is measured to 160/90 and there is no other pathological findings on clinical examination. His fasting blood glucose is measured to 5.8 mmol/L (capillary). Slide33:  If his fasting blood glucose was measured again a few days later at your practice: How low would that value need to be before you would believe that his actual blood glucose was lower than when measured previously? __,__ mmol/L How high would that value need to be before you would believe that his actual blood glucose was higher than when measured previously? __,__ mmol/L Calculations:  Calculations Feedback report to the participants:  Feedback report to the participants Information on Own results compared to others Corresponding analytical quality Information on analytical and biological variation Guidelines for use of the actual laboratory tests Next will be microalbumine:  Next will be microalbumine Questionnaire to diabetic patients:  Questionnaire to diabetic patients Imagine that you have measured your blood glucose level to be 8.0 mmol/L To what value do you think your blood glucose must increase before you would be sure that it represents a true increase? ___ Conclusions:  Conclusions Instruments for selfmonitoring of blood glucose must have a CVa < 5% and a bias of < 5% in the hands of the diabetic patients; i.e. A TE < 13%. Clin Chem 2001; 47: 67-73 Slide41:  Glucose (mmol/L) Clin Chem 2002; 48: 994-1003 How should patients control their performance and the instruments?:  How should patients control their performance and the instruments? User assessment at the physicians office? User assessment at the pharmacy? External quality control? Slide43:  Thank you

Related presentations


Other presentations created by Nastasia

ICU acquired weakness Ron Jou
24. 10. 2007
0 views

ICU acquired weakness Ron Jou

ppt 14
14. 12. 2007
0 views

ppt 14

griffith seminar 150306
01. 10. 2007
0 views

griffith seminar 150306

Ch 2 Climate Causes of Aridity
03. 10. 2007
0 views

Ch 2 Climate Causes of Aridity

Anti Anxiety Agents
28. 11. 2007
0 views

Anti Anxiety Agents

lect8
04. 12. 2007
0 views

lect8

25271
06. 12. 2007
0 views

25271

GoalSetting
10. 12. 2007
0 views

GoalSetting

Consol Serra
25. 10. 2007
0 views

Consol Serra

3 The Model Treaties
29. 10. 2007
0 views

3 The Model Treaties

L08 MDS
31. 10. 2007
0 views

L08 MDS

CHAP09
02. 11. 2007
0 views

CHAP09

noaa updta isom 2004
05. 11. 2007
0 views

noaa updta isom 2004

oct energy narayana
05. 11. 2007
0 views

oct energy narayana

TS1 2 1
04. 10. 2007
0 views

TS1 2 1

Case Volkswagen
16. 11. 2007
0 views

Case Volkswagen

school pp
19. 11. 2007
0 views

school pp

hedgefunds bubble slides
20. 11. 2007
0 views

hedgefunds bubble slides

fuel tank safety bahrami medal
06. 11. 2007
0 views

fuel tank safety bahrami medal

POA nsrc 2005 02 15
26. 11. 2007
0 views

POA nsrc 2005 02 15

Brand Presentation UofA
23. 11. 2007
0 views

Brand Presentation UofA

who are you
28. 12. 2007
0 views

who are you

WM TB2
31. 12. 2007
0 views

WM TB2

NDM Workshop
04. 01. 2008
0 views

NDM Workshop

chap11a
07. 01. 2008
0 views

chap11a

nutrient murray
07. 01. 2008
0 views

nutrient murray

harmon05
24. 12. 2007
0 views

harmon05

5 coldwar lesson
25. 12. 2007
0 views

5 coldwar lesson

Program Overview2
01. 01. 2008
0 views

Program Overview2

Kaal Dorst Beyond MIP final
21. 11. 2007
0 views

Kaal Dorst Beyond MIP final

Presentation Barbarosie
01. 12. 2007
0 views

Presentation Barbarosie

GRP 12 LA buffet
12. 12. 2007
0 views

GRP 12 LA buffet

SSA Presentation
05. 01. 2008
0 views

SSA Presentation

dnttour leader english
02. 10. 2007
0 views

dnttour leader english

cg 00 36
20. 02. 2008
0 views

cg 00 36

copyright authorship
27. 02. 2008
0 views

copyright authorship

masterclass
13. 11. 2007
0 views

masterclass

McCreight
05. 03. 2008
0 views

McCreight

Ling Chen
27. 03. 2008
0 views

Ling Chen

RameshNarayanSciWrit ers
29. 11. 2007
0 views

RameshNarayanSciWrit ers

6 2buscycle
13. 04. 2008
0 views

6 2buscycle

CAP June07
15. 11. 2007
0 views

CAP June07

2007 01vadmSullivan
06. 11. 2007
0 views

2007 01vadmSullivan

cabwrcpresentation final
11. 12. 2007
0 views

cabwrcpresentation final

GoetzAccelChange
21. 12. 2007
0 views

GoetzAccelChange

Internet QoS Technique
04. 01. 2008
0 views

Internet QoS Technique

Blue
16. 11. 2007
0 views

Blue

nabucco Sep14 2007
26. 10. 2007
0 views

nabucco Sep14 2007

PPT Mearns Intro2 health 2006
25. 10. 2007
0 views

PPT Mearns Intro2 health 2006

rm2403
30. 10. 2007
0 views

rm2403

FAO Peres Oct06
30. 10. 2007
0 views

FAO Peres Oct06

KateBTina
12. 12. 2007
0 views

KateBTina

urbana web
21. 11. 2007
0 views

urbana web

xml in mozilla
28. 12. 2007
0 views

xml in mozilla

Pablo
07. 11. 2007
0 views

Pablo

cookware energy2
03. 01. 2008
0 views

cookware energy2

ponencia NOM 030
15. 11. 2007
0 views

ponencia NOM 030

La civilisation romaine
30. 10. 2007
0 views

La civilisation romaine

Stata20060629
02. 01. 2008
0 views

Stata20060629

Permanentflowers
07. 12. 2007
0 views

Permanentflowers

s1310 amer yahia
03. 12. 2007
0 views

s1310 amer yahia